932 related articles for article (PubMed ID: 25655625)
1. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
2. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
3. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
4. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
Wong DF; Rosenberg PB; Zhou Y; Kumar A; Raymont V; Ravert HT; Dannals RF; Nandi A; Brasić JR; Ye W; Hilton J; Lyketsos C; Kung HF; Joshi AD; Skovronsky DM; Pontecorvo MJ
J Nucl Med; 2010 Jun; 51(6):913-20. PubMed ID: 20501908
[TBL] [Abstract][Full Text] [Related]
5. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
6. Dual-phase [18F]florbetapir in frontotemporal dementia.
Asghar M; Hinz R; Herholz K; Carter SF
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):304-311. PubMed ID: 30569187
[TBL] [Abstract][Full Text] [Related]
7. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
8. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
9. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
[TBL] [Abstract][Full Text] [Related]
10. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
Fleisher AS; Chen K; Liu X; Ayutyanont N; Roontiva A; Thiyyagura P; Protas H; Joshi AD; Sabbagh M; Sadowsky CH; Sperling RA; Clark CM; Mintun MA; Pontecorvo MJ; Coleman RE; Doraiswamy PM; Johnson KA; Carpenter AP; Skovronsky DM; Reiman EM
Neurobiol Aging; 2013 Jan; 34(1):1-12. PubMed ID: 22633529
[TBL] [Abstract][Full Text] [Related]
12. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
13. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
[TBL] [Abstract][Full Text] [Related]
14. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
15. Dual-phase
Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
17. Impact of molecular imaging on the diagnostic process in a memory clinic.
Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
[TBL] [Abstract][Full Text] [Related]
18. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
19. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.
Hsiao IT; Huang CC; Hsieh CJ; Wey SP; Kung MP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):908-20. PubMed ID: 23412134
[TBL] [Abstract][Full Text] [Related]
20. Differences in gray and white matter
Son HJ; Oh JS; Roh JH; Seo SW; Oh M; Lee SJ; Oh SJ; Kim JS
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):357-366. PubMed ID: 30109402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
